casticin has been researched along with Breast-Neoplasms* in 3 studies
3 other study(ies) available for casticin and Breast-Neoplasms
Article | Year |
---|---|
Antitumor activity of an Artemisia annua herbal preparation and identification of active ingredients.
Artemisia annua L. has gained increasing attention for its anticancer activity. However, beside artemisinin, less is known about the possible bioactive ingredients of Artemisia annua and respective herbal preparations. We hypothesized that, in addition to artemisinin, Artemisia annua preparations might contain multiple ingredients with potential anticancer activity.. An extract of an artemisinin-deficient Artemisia annua herbal preparation exhibits potent anticancer activity against triple negative human breast cancer. New active ingredients of Artemisia annua extract with potential anticancer activity have been identified. Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Artemisia annua; Artemisinins; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Line, Tumor; Female; Flavones; Flavonoids; Humans; Leukocytes, Mononuclear; Lung Neoplasms; Mice; Mice, Nude; Plant Extracts; Xenograft Model Antitumor Assays | 2019 |
Casticin inhibits breast cancer cell migration and invasion by down-regulation of PI3K/Akt signaling pathway.
Topics: Animals; Breast Neoplasms; Cell Line, Tumor; Cell Movement; Cell Proliferation; Female; Flavonoids; Gene Expression Regulation, Neoplastic; Humans; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Mice; Mitogen-Activated Protein Kinase 8; Neoplasm Invasiveness; Neoplasm Metastasis; Oncogene Protein v-akt; Phosphatidylinositol 3-Kinases; Phosphorylation; Proto-Oncogene Proteins c-fos; Signal Transduction; Xenograft Model Antitumor Assays | 2018 |
[Vitexicarpin affects proliferation and apoptosis in mutated p53 breast cancer cell].
To elucidate the effect of proliferation and apoptosis induced by vitexicarpin in mutated p53 Hs578T cell line and study the expression of c-Myc, p21 and Bcl-2 protein in Hs578T and wild p53 MCF-7 cell pre-treated with vitexicarpin.. Cells were treated with various concentrations of vitexicarpin (0, 0.1, 0.2, 0.5, 1.0 micromol/L). MTT assays were used to detect cell proliferation at different time points with different doses of vitexicarpin. TUNEL assays were performed to examine apoptosis in cells pretreated with vitexicarpin. The authors detected three main proteins involved in apoptosis: c-Myc, bcl-2 and p21 protein in various concentrations of vitexicarpin-treated cells. To understand the function of c-Myc protein in the effect of vitexicarpin, the authors transiently transfected c-Myc protein in Hs578T cell and detected the cellular effect of vitexicarpin.. Proliferation of Hs578T and MCF-7 cells were inhibited markedly by vitexicarpin at concentrations above 0.2 micromol/L (IC50 = 0.25 micromol/L and 0.53 micromol/L at 72 h respectively). TUNEL assays revealed that the rates of TUNEL positive cells were 10.15%, 27.33% and 35.34% when exposing Hs578T cells to 0.1, 0.2 and 0.5 micromol/L of vitexicarpin respectively. In control cells, the rates of TUNEL positive cells were 4.65%. Cells pretreated with higher concentrations of vitexicarpin expressed less c-Myc and Bcl-2 in Hs578T cells.In contrast, p21 decreased when cells were treated with the same conditions. When c-Myc transient transfection was performed in vitexicarpin-treated cells, the effect of p21 and Bcl-2 disappeared. The proliferative function of vitexicarpin declined in Hs578T/c-Myc cells. When treated with 0.5 micromol/L vitexicarpin, A value increased 1.53 times at 72 h. Conversely, A value decreased 48% at the same condition in MCF-7/c-Myc cells.. The suppressing mechanism of vitexicarpin for malignant tumors is through c-Myc in p53 mutated Hs578T cells. And it is multi-directional and varies in different cells. Topics: Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Female; Flavonoids; Humans; Mutation; Tumor Suppressor Protein p53 | 2010 |